FATE FATE THERAPEUTICS INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$2.83

Period return

+1.58 (+126.40%)

Volume

1.1M

2026-07-21O $2.86 H $2.86 L $2.78 C $2.83MA5 $2.83MA20 $2.73MA60 $2.26MA120 $1.76

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 11.Highin 21 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 04.LowBUY3 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 10. 31.MediumBUY9 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 10. 27.MediumBUY9 months ago
Wedbush: Outperform
US analyst rating / recommendation change.
2025. 10. 27.LowHOLD9 months ago
Needham: Hold
US analyst rating / recommendation change.
2025. 08. 13.LowHOLD11 months ago
Wells Fargo: Equal-Weight
US analyst rating / recommendation change.
2025. 06. 12.LowHOLDlast year
Needham: Hold
US analyst rating / recommendation change.
2025. 05. 14.LowBUYlast year
Barclays: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $5.41 · 9 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
HQ: San Diego, CA, United States
Fiscal year end: —
Employees: 161
IPO date: —

View details →

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 11.	After market close (AMC)	$-0.26	—	—	$943.86K	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.32	—	—	$1.63M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-1.19	—	—	$11.77M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.79	—	—	$8.7M	Reported

FATE THERAPEUTICS INC

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 04.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 10. 31.	HC Wainwright & Co.	—	Upgrade	Neutral → Buy	—	HC Wainwright & Co.: Neutral → Buy
2025. 10. 27.	Wedbush	—	Upgrade	Neutral → Outperform	—	Wedbush: Neutral → Outperform
2025. 10. 27.	Needham	—	Maintain	Hold → Hold	—	Needham: Hold
2025. 08. 13.	Wells Fargo	—	Maintain	Equal-Weight → Equal-Weight	—	Wells Fargo: Equal-Weight
2025. 06. 12.	Needham	—	Maintain	Hold → Hold	—	Needham: Hold

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	3,466,786	$4.16M	0.00%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	1,734,064	$1.7M	0.00%	—	New position
3	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	1,527,986	$1.5M	0.00%	—	New position
4	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	43,119	$51.74K	0.00%	—	New position